patritumab
daiichi sankyo
['bcsm', 'patritumab', 'mbc']
patritumab deruxtecan (her3-dxd) - phase 1/2 study in her3-expressing mbc has clinical activity - data presented by ian krop. no clear link between her3 expression and response to therapy. study shows her3 expression tends to be fluid and changes over time. #bcsm #asco22
Breast & gyn med onc @valleyhospital in NJ. Focus on survivorship and ?????? onc. All opinions my own. Retweets not endorsements. Host of INTERLUDE podcast ??